GIC-102, Intravenous Allogeneic NK Cells, in Subjects With Advanced Solid Cancers and R/R Hematologic Malignancies

Phase 1/2 Unknown 50 enrolled GI Cell, Inc.

Non-randomizedSingle-groupOpen-labelTreatment

Summary

This is a first-in-human trial to investigate the safety, tolerability, pharmacokinetics, pharmacodynamics, and antitumor effects of GIC-102 in patients with advanced solid tumors, relapsed/refractory non-hodgkin lymphoma, and multiple myeloma.

Timeline

Start: 2023-04-28
Primary completion: 2025-12-30
Completion: 2026-06-30

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	GIC-102	Cell therapy	1e+09 cells	Intravenous
Subject	GIC-102	Cell therapy	3e+09 cells	Intravenous
Subject	GIC-102	Cell therapy	1e+10 cells	Intravenous

GIC-102, Intravenous Allogeneic NK Cells, in Subjects With Advanced Solid Cancers and R/R Hematologic Malignancies

Summary

Timeline

Drugs

Indications